Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing therapies for rare neurological diseases. Its lead product WAKIX (pitolisant) is approved in the US for excessive daytime sleepiness or cataplexy in adult narcolepsy patients. The company has a robust late-stage pipeline with additional indications under development including Prader-Willi syndrome, myotonic dystrophy type I, Fragile X syndrome, rare epilepsies, and more. Recent clinical data highlight significant wake-promoting effects of new candidates such as BP1.15205.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hamoni.